Viramal Appoints Women’s Healthcare Expert, William Bologna, as Chairman of the Board of Directors

NEW YORK–(BUSINESS WIRE)–Viramal, (“the Company”), an emerging specialty pharmaceutical company
developing therapeutics that improve the quality of women’s health,
today announced the appointment of William Bologna as Chairman of the
Board of Directors, effective immediately. Mr. Bologna is also the
Company’s chief scientist.

Bill Bologna is a pioneer in women’s healthcare who has successfully
developed and licensed market-leading products in fertility and female
sexual health. He co-founded Nasdaq listed Columbia Laboratories (now
Juniper Pharmaceuticals) in 1986, one of the first publicly traded
women’s health companies in the United States. Under his tenure, the
company commercialized Crinone®, Replens®, RepHresh®, Striant®,
Advantage-S and other well-known products, a number of which have
regulatory approval to be sold in over 90 countries.

During his career, Mr. Bologna has been granted more than 50 patents
covering new drug delivery systems, unique pharmaceutical compositions
and methods for treating female health disorders, with another eight
patents pending. Mr. Bologna’s patents cover women’s health disorders
such as endometriosis, infertility, premature labor, dysmenorrhea, and
vaginal infections, among other conditions.

“Bill Bologna is a leader in female healthcare and we are thrilled to
welcome him to Viramal as our Chairman. Bill has a successful track
record of developing and commercializing novel therapies that improve
the quality of women’s health,” said Oliver Bates, Viramal’s Chief
Executive Officer. “His highly relevant experience directly aligns with
Viramal’s strategy to produce a step change in existing female
healthcare products, as well as develop innovative products that target
unmet therapeutic areas, by leveraging our unique platform
delivery technologies
.”

“Viramal has a highly differentiated portfolio of products that should
significantly improve the standard of care available to women and I am
excited to capitalize on this opportunity,” said Mr. Bologna. “Our
treatments, which span fertility, menopausal hormone therapy,
contraception and sexual health, overcome significant side effects
prevalent in existing products in what have traditionally been
underserved markets. I look forward to working with the Board of
Directors and management
team
to advance Viramal’s unique product
portfolio
. We expect to launch the majority of our products within
the next several years and capture significant commercial opportunities
both in the Unites States and worldwide.”

Prior to working at Juniper Pharmaceuticals, in 1980 Mr. Bologna founded
one of the first medical consulting, marketing and advertising companies
in the United States, Bologna International, which provided services to
multinational pharmaceutical companies. In addition, Mr. Bologna has
held senior management positions in international medical consulting and
publishing companies.

He holds an MBA degree and a Bachelor of Science in Pharmacy from
Fordham University.

About Viramal

Viramal is an emerging specialty pharmaceutical company focused on the
development of therapeutics that improve the quality of women’s health.
The Company’s well-recognized management team has pioneered
market-leading products in fertility and female sexual health, having
successfully developed and licensed Crinone®, Replens® and RepHresh®.
Viramal produces a step change in these existing products, as well as
develops innovative products that target unmet therapeutic areas, by
leveraging novel platform delivery technologies that offer greater
safety, efficacy and patient acceptability with far fewer side effects.
The Company’s robust women’s health clinical development pipeline
includes treatments for fertility, menopausal hormone therapy,
contraception and sexual health. In addition, Viramal’s only male
product, TestoCream (transdermal delivery of testosterone), has shown
81% success in a partially completed Phase III study. Please visit www.viramal.com
for more information.

Contacts

Investors
MBS Value Partners
Katja
Buhrer, 212-661-7004
katja.buhrer@mbsvalue.com